Sihuan Pharmaceutical said it has successfully enrolled the first patient in the United States for its Phase I clinical trial of Pirotinib developed by Shandong XuanZhu Pharma, a wholly owned subsidiary, working with Covance on preparation and initiation. The patient was administered with the first dose on April 8, the company said in a release to the Hong Kong Stock Exchange. Pirotinib is a novel therapy aimed at lung, gastric and other cancers, the company said. It was granted clinical trial approval by the U.S. FDA on Nov. 26 2014. Release (PDF)